RELEASE DATE:  February 24, 2003

PA NUMBER:  PA-03-073

March 2, 2006 (NOT-OD-06-046) – Effective with the June 1, 2006 submission date, 
all R03, R21, R33 and R34 applications must be submitted through using 
the electronic SF424 (R&R) application. Accordingly, this funding opportunity 
expires on the date indicated below. Replacement R21 (PA-06-157) and R01 (PA-06-158)
funding opportunity announcements have been issued for the submission date of June 1,
2006 and submission dates thereafter. 

EXPIRATION DATE:  March 02, 2006

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

93.849 NIDDK Kidney Disease, Urology and Hematology Research  


o Purpose of the PA
o Research Objectives
o Mechanism(s) of Support 
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Where to Send Inquiries
o Submitting an Application
o Peer Review Process
o Review Criteria
o Award Criteria
o Required Federal Citations


The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 
through its Division of Kidney, Urologic and Hematologic Diseases (DKUHD) 
invites experienced and new investigators to submit research grant 
applications to pursue basic and applied investigations in order to better 
understand the etiology and pathogenesis of Polycystic Kidney Disease (PKD), 
in both its autosomal dominant and autosomal recessive forms.  Such 
applications may examine the genetic determinants, and cellular and molecular 
mechanisms, which disrupt normal kidney function; mechanisms of cyst 
formation and growth; development of experimental model systems; development 
of markers of disease progression; and the identification of innovative 
therapeutic interventions and gene targeted strategies to prevent progressive 
renal insufficiency due to this disorder.  The intent of this Program 
Announcement (PA) is to intensify investigator-initiated research, to attract 
new investigators to the field, and to increase interdisciplinary research.  
The ultimate aim is to facilitate PKD-related research studies, which will 
provide the basis for new therapeutic approaches.  



Polycystic Kidney Disease is a serious and costly disease.  As many as 600,000 
people in the USA have been estimated to have PKD. According to the USRDS 
registry PKD accounts for 2.3% of the incident cases of reported ESRD.  Recent 
important advances in understanding the molecular basis of autosomal dominant 
PKD (i.e., ADPKD1 and ADPKD2) and autosomal recessive PKD (i.e., PKHD1) have 
generated intense interest and have provided investigators with important 
research opportunities.  Although certain topics are already receiving careful 
study, the timely opportunities to discover more about the etiology and 
pathogenesis of PKD in particular, and the related cellular and molecular 
mechanisms that determine kidney function in general, need to be addressed.  
These investigations, largely fundamental, are likely to generate, in the 
foreseeable future, a variety of possible strategies for clinical 
intervention.  The focus of this research initiative is investment in the 
groundwork that will facilitate the eventual testing of such strategies.  
Substantial difficulties exist in the translation of fundamental insight into 
therapeutic methods, including the slow rate of progression of the disease in 
patients and the difficulty of monitoring cyst growth.  The development of 
experimental models that mimic human disease is an important goal.  Also 
critical will be the development of improved methods to monitor progression of 
disease in PKD patients.  Development of imaging methods that assess cyst 
growth and provide markers of disease progression could markedly improve the 
feasibility of clinical trials.  Another important area of investigation is 
the identification of genetic modifiers of human ADPKD to elucidate the 
interactions between PKD-susceptibility loci and their genetic modifiers.

Research Goals and Scope

It is the intent of this solicitation to invite applications from 
investigators with diverse scientific interests, who wish to apply their 
expertise into basic and applied research to enhance the understanding of the 
etiology and pathogenesis of PKD, both autosomal dominant PKD (ADPKD) and 
autosomal recessive PKD (ARPKD); the genetic determinants and cellular and 
molecular mechanisms which disrupt normal kidney function; the mechanisms of 
cyst formation and growth at the cellular and molecular levels; the 
development of experimental model systems; the development of imaging methods 
to assess cyst growth and disease progression; and research studies aimed at 
the identification of therapeutic opportunities and gene targeted strategies 
to prevent progressive renal insufficiency due to this disorder.

The NIDDK convened a strategic planning meeting on Polycystic Kidney Disease 
in July 2002.  The report of that task force is available.  That planning group 
outlined a series of goals for PKD research for the next five years including 
the following:

o  To define the function of molecules and pathways that cause, aggravate or 
ameliorate PKD.

o  To improve methods of mutation detection in human polycystic kidney 
diseases, and assess the effect of the more common specific mutations on 
protein function and clinical phenotype. 

o To identify all genes responsible for both ADPKD and ARPKD in humans and in 
relevant rodent models.

o To identify in rodent models, and possibly non-mammalian models genetic loci 
and specific genes that modify the clinical phenotype.

o To develop improved animal models of ADPKD/ARPKD.

o To assess the value of potential therapeutic targets to slow the progression 
of disease in both ADPKD and ARPKD.  Biological targets to be assessed include 
renin-angiotensin system, growth factor signaling, fluid secretion and 

Specific examples of projects that would be responsive to this solicitation 
are listed below.  These examples are meant only to provide broad illustration 
of potential directions, and not to be restrictive:

Protein characterization studies that determine the subcellular localization 
and protein binding partners of the ADPKD/ARPKD gene products.  Studies to 
identify the polycystins and fibrocystin/polyductin ligands/receptors.  

Studies of polycystin channel function such as studies of gating and 
activation mechanisms for normal and mutant proteins. Studies that 
characterize polycystin signaling in both normal epithelia and cyst-lining 

Studies examining the role of cilia in PKD, including studies of the role of 
polycystins as mechanically-sensitive cation channels in the primary cilium, 
chemosensory and flow sensing functions of the primary cilium, effect of 
defective polycystins on cilial function and the potential role of the cilium 
in the regulation of tubule epithelial geometry and cyst formation. 

Development of new methods useful for basic PKD research including 
development of cell models and non-mammalian animal models to facilitate easy 
manipulation and study of PKD pathways, genetic screens, gene disruption, 
small molecule/drug screens, and structural studies. 

Studies to map and identify the human ADPKD genes that are still unknown.

Studies to produce improved rodent models.

Studies to define the splicing/cleavage and transcriptional regulation of PKD 
gene products.

Studies to map identify modifier loci and ultimately gene products for 
rodent models and human disease.

Patient data collections that compile information on affected individuals and 
families, for use by the research community for such purposes as genotype-
phenotype correlations or determination of the natural history of disease.

Development of disease markers and improved methods to monitor disease 

Development of new therapeutic strategies in both animal models and patients. 


This PA will use the NIH R01 and R21 award mechanism(s).  

Exploratory/developmental grants (R21) are limited to 2 years and $100,000 
per year in direct costs.  As an applicant, you will be solely responsible 
for planning, directing, and executing the proposed project.  

This PA uses just-in-time concepts.  It also uses the modular as well as the 
non-modular budgeting formats (see  Specifically, if 
you are submitting an application with direct costs in each year of $250,000 
or less, use the modular format.  Otherwise follow the instructions for non-
modular research grant applications.  This program does not require cost 
sharing as defined in the current NIH Grants Policy Statement at 


You may submit (an) application(s) if your institution has any of the 
following characteristics: 

o For-profit or non-profit organizations 
o Public or private institutions, such as universities, colleges, hospitals, 
and laboratories 
o Units of State and local governments
o Eligible agencies of the Federal government  
o Domestic or foreign
o Faith-based or community-based organizations 


Any individual with the skills, knowledge, and resources necessary to carry 
out the proposed research is invited to work with their institution to 
develop an application for support.  Individuals from underrepresented racial 
and ethnic groups as well as individuals with disabilities are always 
encouraged to apply for NIH programs.   


We encourage your inquiries concerning this PA and welcome the opportunity to 
answer questions from potential applicants.  Inquiries may fall into two 
areas:  scientific/research, and financial or grants management issues:

o Direct your questions about scientific/research issues to:

Catherine M. Meyers, M.D.
Program Director of Inflammatory Kidney Diseases
Division of Kidney, Urologic and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Blvd., Rm. 641
Bethesda, MD  20892-5458
Telephone:  (301)594-7717
FAX:  (301)480-3510

o Direct your questions about financial or grants management matters to:

Ms. Aretina Perry-Jones
Grants Management Specialist
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Blvd., Room 745 MSC 5456
Bethesda, MD  20892-5456
Telephone:  (301) 594-8862
FAX:  (301) 480-3504


Applications must be prepared using the PHS 398 research grant application 
instructions and forms (rev. 5/2001).  The PHS 398 is available at in an interactive 
format.  For further assistance contact GrantsInfo, Telephone (301) 710-0267, 

APPLICATION RECEIPT DATES: Applications submitted in response to this program 
announcement will be accepted at the standard application deadlines, which 
are available at  Application 
deadlines are also indicated in the PHS 398 application kit.

SPECIFIC INSTRUCTION FOR R21 APPLICATIONS:  All application instructions 
outlined in the PHS 398 application kit is to be followed, with the following 
requirements for R21 applications:  

1.  R21 applications will use the "MODULAR GRANT" and "JUST-IN-TIME" 
concepts, with direct costs requested in $25,000 modules, up to the total 
direct costs limit of $100,000 per year. 

2.  Although preliminary data are not required for an R21 application, they 
may be included.

3.  Sections a-d of the Research Plan of the R21 application may not exceed 
15 pages, including tables and figures. 

4.  R21 appendix materials should be limited, as is consistent with the 
exploratory nature of the R21 mechanism, and should not be used to circumvent 
the page limit for the research plan.   Copies of appendix material will only 
be provided to the primary reviewers of the application and will not be 
reproduced for wider distribution.  The following materials may be included 
in the appendix:

o   Up to five publications, including manuscripts (submitted or accepted 
for publication), abstracts, patents, or other printed materials 
directly relevant to the project.  These may be stapled as sets.
o   Surveys, questionnaires, data collection instruments, and clinical 
protocols.  These may be stapled as sets.
o   Original glossy photographs or color images of gels, micrographs, etc., 
provided that a photocopy (may be reduced in size) is also included 
within the 15 page limit of items a-d of the research plan.

requesting up to $250,000 per year in direct costs must be submitted in a 
modular grant format.  The modular grant format simplifies the preparation of 
the budget in these applications by limiting the level of budgetary detail.  
Applicants request direct costs in $25,000 modules.  Section C of the 
research grant application instructions for the PHS 398 (rev. 5/2001) at includes step-by-step 
guidance for preparing modular grants.  Additional information on modular 
grants is available at

Applications requesting $500,000 or more in direct costs for any year must 
include a cover letter identifying the NIH staff member within one of NIH 
institutes or centers who has agreed to accept assignment of the application.   

Applicants requesting more than $500,000 must carry out the following steps:

1) Contact the IC program staff at least 6 weeks before submitting the 
application, i.e., as you are developing plans for the study; 

2) Obtain agreement from the IC staff that the IC will accept your 
application for consideration for award; and,
3) Identify, in a cover letter sent with the application, the staff member 
and IC who agreed to accept assignment of the application.  

This policy applies to all investigator-initiated new (type 1), competing 
continuation (type 2), competing supplement, or any amended or revised 
version of these grant application types. Additional information on this 
policy is available in the NIH Guide for Grants and Contracts, October 19, 
2001 at 

SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of 
the application, including the checklist, and five signed photocopies in one 
package to:

Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD  20892-7710
Bethesda, MD  20817 (for express/courier service)

APPLICATION PROCESSING: Applications must be mailed on or before the receipt 
dates described at  The CSR will 
not accept any application in response to this PA that is essentially the 
same as one currently pending initial review unless the applicant withdraws 
the pending application.  The CSR will not accept any application that is 
essentially the same as one already reviewed.  This does not preclude the 
submission of a substantial revision of an application already reviewed, but 
such application must include an Introduction addressing the previous 

Although there is no immediate acknowledgement of the receipt of an 
application, applicants are generally notified of the review and funding 
assignment within 8 weeks.


Applications submitted for this PA will be assigned on the basis of 
established PHS referral guidelines.  An appropriate scientific review group 
convened in accordance with the standard NIH peer review procedures 
( will evaluate applications for scientific 
and technical merit.  

As part of the initial merit review, all applications will:

o Receive a written critique
o Undergo a selection process in which only those applications deemed to have 
the highest scientific merit, generally the top half of applications under 
review, will be discussed and assigned a priority score
o Receive a second level review by the appropriate national advisory council 
or board  


The goals of NIH-supported research are to advance our understanding of 
biological systems, improve the control of disease, and enhance health.  In 
the written comments, reviewers will be asked to discuss the following 
aspects of the application in order to judge the likelihood that the proposed 
research will have a substantial impact on the pursuit of these goals: 

o Significance 
o Approach 
o Innovation
o Investigator
o Environment
The scientific review group will address and consider each of these criteria 
in assigning the application's overall score, weighting them as appropriate 
for each application.  The application does not need to be strong in all 
categories to be judged likely to have major scientific impact and thus 
deserve a high priority score.  For example, an investigator may propose to 
carry out important work that by its nature is not innovative but is 
essential to move a field forward.

SIGNIFICANCE: Does this study address an important problem? If the aims of 
the application are achieved, how will scientific knowledge be advanced? What 
will be the effect of these studies on the concepts or methods that drive 
this field?

APPROACH: Are the conceptual framework, design, methods, and analyses 
adequately developed, well-integrated, and appropriate to the aims of the 
project? Does the applicant acknowledge potential problem areas and consider 
alternative tactics?

INNOVATION: Does the project employ novel concepts, approaches or methods? 
Are the aims original and innovative? Does the project challenge existing 
paradigms or develop new methodologies or technologies?

INVESTIGATOR: Is the investigator appropriately trained and well suited to 
carry out this work? Is the work proposed appropriate to the experience level 
of the principal investigator and other researchers (if any)?

ENVIRONMENT: Does the scientific environment in which the work will be done 
contribute to the probability of success? Do the proposed experiments take 
advantage of unique features of the scientific environment or employ useful 
collaborative arrangements? Is there evidence of institutional support?  

ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, the following 
items will be considered in the determination of scientific merit and the 
priority score:

subjects and protections from research risk relating to their participation 
in the proposed research will be assessed. (See criteria included in the 
section on Federal Citations, below).
plans to include subjects from both genders, all racial and ethnic groups 
(and subgroups), and children as appropriate for the scientific goals of the 
research will be assessed.  Plans for the recruitment and retention of 
subjects will also be evaluated. (See Inclusion Criteria in the sections on 
Federal Citations, below).

be used in the project, the five items described under Section f of the PHS 
398 research grant application instructions (rev. 5/2001) will be assessed.  


DATA SHARING:  The adequacy of the proposed plan to share data. 

BUDGET:  The reasonableness of the proposed budget and the requested period 
of support in relation to the proposed research.


Applications submitted in response to a PA will compete for available funds 
with all other recommended applications.  The following will be considered in 
making funding decisions:  

o Scientific merit of the proposed project as determined by peer review
o Availability of funds 
o Relevance to program priorities


HUMAN SUBJECTS PROTECTION:  Federal regulations (45CFR46) require that 
applications and proposals involving human subjects must be evaluated with 
reference to the risks to the subjects, the adequacy of protection against 
these risks, the potential benefits of the research to the subjects and 
others, and the importance of the knowledge gained or to be gained.

involving Phase I and II clinical trials must include provisions for 
assessment of patient eligibility and status, rigorous data management, 
quality assurance, and auditing procedures.  In addition, it is NIH policy 
that all clinical trials require data and safety monitoring, with the method 
and degree of monitoring being commensurate with the risks (NIH Policy for 
Data Safety and Monitoring, NIH Guide for Grants and Contracts, June 12, 

the NIH that women and members of minority groups and their sub-populations 
must be included in all NIH-supported clinical research projects unless a 
clear and compelling justification is provided indicating that inclusion is 
inappropriate with respect to the health of the subjects or the purpose of the 
research. This policy results from the NIH Revitalization Act of 1993 (Section 
492B of Public Law 103-43).

All investigators proposing clinical research should read the "NIH Guidelines 
for Inclusion of Women and Minorities as Subjects in Clinical Research - 
Amended, October, 2001," published in the NIH Guide for Grants and Contracts 
on October 9, 2001 (
NOT-OD-02-001.html); a complete copy of the updated Guidelines are
available at
_amended_10_2001.htm.  The amended policy incorporates: the use of an NIH
definition of clinical research; updated racial and ethnic categories in
compliance with the new OMB standards; clarification of language governing
NIH-defined Phase III clinical trials consistent with the new PHS Form 398;
and updated roles and responsibilities of NIH staff and the extramural
community.  The policy continues to require for all NIH-defined Phase III
clinical trials that: a) all applications or proposals and/or protocols must
provide a description of plans to conduct analyses, as appropriate, to address
differences by sex/gender and/or racial/ethnic groups, including subgroups if
applicable; and b) investigators must report annual accrual and progress in
conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group 

The NIH maintains a policy that children (i.e., individuals under the age of 
21) must be included in all human subjects research, conducted or supported 
by the NIH, unless there are scientific and ethical reasons not to include 
them. This policy applies to all initial (Type 1) applications submitted for 
receipt dates after October 1, 1998.

All investigators proposing research involving human subjects should read the 
"NIH Policy and Guidelines" on the inclusion of children as participants in 
research involving human subjects that is available at 

policy requires education on the protection of human subject participants for 
all investigators submitting NIH proposals for research involving human 
subjects.  You will find this policy announcement in the NIH Guide for Grants 
and Contracts Announcement, dated June 5, 2000, at

HUMAN EMBRYONIC STEM CELLS (hESC):  Criteria for federal funding of research 
on hESCs can be found at and at  Only 
research using hESC lines that are registered in the NIH Human Embryonic Stem 
Cell Registry will be eligible for Federal funding (see   
It is the responsibility of the applicant to provide the official NIH 
identifier(s)for the hESC line(s)to be used in the proposed research.  
Applications that do not provide this information will be returned without 

Office of Management and Budget (OMB) Circular A-110 has been revised to 
provide public access to research data through the Freedom of Information Act 
(FOIA) under some circumstances.  Data that are (1) first produced in a 
project that is supported in whole or in part with Federal funds and (2) 
cited publicly and officially by a Federal agency in support of an action 
that has the force and effect of law (i.e., a regulation) may be accessed 
through FOIA.  It is important for applicants to understand the basic scope 
of this amendment.  NIH has provided guidance at

Applicants may wish to place data collected under this PA in a public 
archive, which can provide protections for the data and manage the 
distribution for an indefinite period of time.  If so, the application should 
include a description of the archiving plan in the study design and include 
information about this in the budget justification section of the 
application. In addition, applicants should think about how to structure 
informed consent statements and other human subjects procedures given the 
potential for wider use of data collected under this award.

URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals 
for NIH funding must be self-contained within specified page limitations. 
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) 
should not be used to provide information necessary to the review because 
reviewers are under no obligation to view the Internet sites.   Furthermore, 
we caution reviewers that their anonymity may be compromised when they 
directly access an Internet site.

HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to 
achieving the health promotion and disease prevention objectives of "Healthy 
People 2010," a PHS-led national activity for setting priority areas. This PA 
is related to one or more of the priority areas. Potential applicants may 
obtain a copy of "Healthy People 2010" at

AUTHORITY AND REGULATIONS: This program is described in the Catalog of 
Federal Domestic Assistance at and is not subject to the 
intergovernmental review requirements of Executive Order 12372 or Health 
Systems Agency review.  Awards are made under the authorization of Sections 
301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) 
and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All 
awards are subject to the terms and conditions, cost principles, and other 
considerations described in the NIH Grants Policy Statement.  The NIH Grants 
Policy Statement can be found at 

The PHS strongly encourages all grant recipients to provide a smoke-free 
workplace and discourage the use of all tobacco products.  In addition, 
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in 
certain facilities (or in some cases, any portion of a facility) in which 
regular or routine education, library, day care, health care, or early 
childhood development services are provided to children.  This is consistent 
with the PHS mission to protect and advance the physical and mental health of 
the American people.

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.